Acuamark Diagnostics
Howard Johnson is the Vice President, Corporate Development at Lion Biotechnologies, an oncology company developing immunotherapies based on patient-specific T-cells. Entrepreneurial executive with thirty-years of experience in operations, finance, business development, and investor relations at biotechnology companies. A founding investor and initial Board Member of Acorda Therapeutics.
This person is not in the org chart
This person is not in any offices
Acuamark Diagnostics
Acuamark Diagnostics (formerly iCareDx) develops technology which allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable.